Drug news
New device is FDA filed by Genentech to extend period of release of Lucentis
Lucentis(ranibizumab) from Genentech/Roche is approved in the USA for AMD and Macular Edema.The drug is administered by monthly injection into the eye. A new implantable ocular device from ForSight VISION 4 will release Lucentis over a period of months. Genetech/Roche have acquired rights to the device and Genentech has filed an application at the FDA
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.